{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:13:51Z","timestamp":1777853631160,"version":"3.51.4"},"reference-count":68,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Intensive Care Med"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Targeted therapies, molecules in full expansion, are not free of side effects that can lead patients to intensive care. We performed an extensive review of the published evidence and propose a management strategy for acute complications of targeted therapy in critically ill patients with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The literature search was performed in August 2017 using the Ovid Medline system by a scientific librarian and physicians. We made a review of cases admitted in intensive care unit (ICU) and a review of toxicities of grades greater or equal to 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our search selected 59 articles. The main cardiovascular side effects requiring ICU are heart failure, which is generally reversible, severe hypertension, thrombotic and ischemic events, and rhythm disturbances. The main pulmonary side effects are interstitial lung disease essentially caused by crizotinib, respiratory infections, pneumothorax, and alveolar hemorrhage. The main gastrointestinal side effects are fulminant hepatitis that may be fatal, colitis that may be complicated by hemorrhage, and perforation. The main neurological side effect is posterior reversible encephalopathy syndrome essentially caused by bevacizumab. The main other side effects are Steven-Johnson syndrome, necrotizing fasciitis, and anaphylactic reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The side effects induced by targeted therapies may be fatal but are generally potentially reversible. The main treatment includes stopping current therapy and symptomatic management. Treatment rechallenge should be discussed on a case-by-case basis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0885066618787788","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T22:01:22Z","timestamp":1535666482000},"page":"435-448","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of Acute Complications of Targeted Therapy in Patients With Cancer: A Review of Cases Managed in ICU"],"prefix":"10.1177","volume":"34","author":[{"given":"Aureliano","family":"Pistone","sequence":"first","affiliation":[{"name":"Unit\u00e9 de soins intensifs et urgences oncologiques, service de m\u00e9decine interne, Institut Jules Bordet, Universit\u00e9 libre de Bruxelles (ULB), Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8975-6562","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Durieux","sequence":"additional","affiliation":[{"name":"Biblioth\u00e8que des Sciences de la Sant\u00e9, Universit\u00e9 libre de Bruxelles (ULB), Bruxelles, Belgium"},{"name":"Laboratoire de M\u00e9decine Factuelle, Facult\u00e9 de M\u00e9decine, Universit\u00e9 libre de Bruxelles (ULB), Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Grigoriu","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de soins intensifs et urgences oncologiques, service de m\u00e9decine interne, Institut Jules Bordet, Universit\u00e9 libre de Bruxelles (ULB), Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Pascale","family":"Meert","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de soins intensifs et urgences oncologiques, service de m\u00e9decine interne, Institut Jules Bordet, Universit\u00e9 libre de Bruxelles (ULB), Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"key":"bibr1-0885066618787788","first-page":"CD007047","volume":"6","author":"Chan DLH","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr2-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3730"},{"key":"bibr3-0885066618787788","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2013.802838"},{"key":"bibr4-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu086"},{"key":"bibr5-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.12.010"},{"issue":"28","key":"bibr6-0885066618787788","first-page":"e1","volume":"134","author":"Frieling T","year":"2009","journal-title":"Dtsch Med Wochenschr 1946"},{"key":"bibr7-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr139"},{"key":"bibr8-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0330"},{"key":"bibr9-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.10.002"},{"key":"bibr10-0885066618787788","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2006.s.009"},{"issue":"9","key":"bibr11-0885066618787788","first-page":"805","volume":"95","author":"Cony-Makhoul P","year":"2008","journal-title":"Bull Cancer (Paris) [Internet]"},{"key":"bibr12-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2011.05.001"},{"key":"bibr13-0885066618787788","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2016-0081"},{"key":"bibr14-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.04.008"},{"key":"bibr15-0885066618787788","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00238"},{"key":"bibr16-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2015.11.008"},{"key":"bibr17-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1339874"},{"key":"bibr18-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1177\/088506660101600307"},{"key":"bibr19-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq543"},{"key":"bibr20-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.6331"},{"key":"bibr21-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1007\/s13546-015-1161-4"},{"issue":"1","key":"bibr22-0885066618787788","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/cncr.24683","volume":"116","author":"Trent JC","year":"2010","journal-title":"Cancer"},{"key":"bibr23-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7065759"},{"key":"bibr24-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.02.050"},{"key":"bibr25-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.656"},{"key":"bibr26-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm086"},{"key":"bibr27-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn657"},{"key":"bibr28-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2010.25"},{"key":"bibr29-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70003-2"},{"key":"bibr30-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1186\/cc11304"},{"key":"bibr31-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14324"},{"key":"bibr32-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0241"},{"issue":"8","key":"bibr33-0885066618787788","first-page":"1148","volume":"10","author":"Cr\u00e9quit P","year":"2015","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"bibr34-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0851"},{"issue":"1","key":"bibr35-0885066618787788","first-page":"e1","volume":"8","author":"van Geffen WH","year":"2013","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"bibr36-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-8-335"},{"key":"bibr37-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.8.1066"},{"key":"bibr38-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0434-6"},{"key":"bibr39-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1678-1"},{"key":"bibr40-0885066618787788","doi-asserted-by":"crossref","unstructured":"Frantzen L, Rondeau-Lutz M, Mosquera F, Martinez C, Labani A, Weber JC. Syndrome d\u2019enc\u00e9phalopathie post\u00e9rieure et atteinte cardiaque r\u00e9versibles sous b\u00e9vacizumab. 2015. \/data\/revues\/02488663\/v37i1\/S0248866315004609\/[Internet].","DOI":"10.1016\/j.revmed.2015.04.011"},{"key":"bibr41-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcr139"},{"key":"bibr42-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052954"},{"key":"bibr43-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052954"},{"key":"bibr44-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.10.1475"},{"key":"bibr45-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03119.x"},{"key":"bibr46-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0692-2"},{"key":"bibr47-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-008-9282-8"},{"key":"bibr48-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2007.01658.x"},{"issue":"1","key":"bibr49-0885066618787788","first-page":"80","volume":"17","author":"Lau PCP","year":"2011","journal-title":"Hong Kong Med J Xianggang Yi Xue Za Zhi"},{"key":"bibr50-0885066618787788","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110637"},{"key":"bibr51-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.1110"},{"issue":"8","key":"bibr52-0885066618787788","first-page":"e73","volume":"8","author":"Yanagisawa S","year":"2013","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"bibr53-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2013.12.004"},{"issue":"8","key":"bibr54-0885066618787788","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3760\/cma.j.issn.0366-6999.20132564","volume":"127","author":"Ji Y","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"bibr55-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu074"},{"key":"bibr56-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1159\/000218097"},{"key":"bibr57-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-198"},{"key":"bibr58-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1177\/1078155209360853"},{"key":"bibr59-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0085-6"},{"issue":"4","key":"bibr60-0885066618787788","first-page":"445","volume":"15","author":"Melichar B","year":"2007","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"bibr61-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.04.011"},{"key":"bibr62-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802314720"},{"key":"bibr63-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"bibr64-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200710-1501OC"},{"key":"bibr65-0885066618787788","unstructured":"Food and Drug Administration. Prescribing information Xalkori\u00ae (crizotinib). Silver Spring, Maryland: Food and Drug Administration; 2013."},{"key":"bibr66-0885066618787788","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906"},{"issue":"9","key":"bibr67-0885066618787788","first-page":"451","volume":"5","author":"Kang SP","year":"2007","journal-title":"J Support Oncol"},{"issue":"2","key":"bibr68-0885066618787788","first-page":"206","volume":"359","author":"Nochy D","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Journal of Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0885066618787788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0885066618787788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0885066618787788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:55:19Z","timestamp":1777503319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0885066618787788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1177\/0885066618787788"],"URL":"https:\/\/doi.org\/10.1177\/0885066618787788","relation":{},"ISSN":["0885-0666","1525-1489"],"issn-type":[{"value":"0885-0666","type":"print"},{"value":"1525-1489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]}}}